Using Esmolol to Improve Oxygen Levels in Patients with Acute Respiratory Distress Syndrome
Effects of Esmolol on Oxygenation Index by Controlling Heart Rate in Patients With Acute Respiratory Distress Syndrome
This study is testing if the heart medication Esmolol can help improve oxygen levels and reduce the time on a ventilator for people with Acute Respiratory Distress Syndrome in the ICU.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 178 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06013319 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Esmolol, a selective β1 receptor blocker, on patients with Acute Respiratory Distress Syndrome (ARDS) who are undergoing mechanical ventilation in the ICU. The study aims to determine if Esmolol can improve the oxygenation index, reduce mechanical ventilation time, and lower 28-day mortality by controlling heart rate and reducing inflammation. Patients aged 18-65 with specific heart rate criteria will be randomly assigned to either a treatment group receiving Esmolol or a control group. The trial will assess various outcomes related to oxygenation and organ function.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with ARDS who require mechanical ventilation and have a heart rate between 95 and 120 beats per minute.
Not a fit: Patients with bradycardia, significant heart block, or contraindications to beta-blockers will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve oxygenation and reduce mortality in ARDS patients.
How similar studies have performed: While there are limited studies on Esmolol in ARDS, previous research has shown promising results in improving oxygenation and reducing inflammation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meeting the 2012 Berlin diagnostic criteria for acute respiratory distress syndrome; * Aged between 18-65 years (inclusive); * 95 times/min ≤ heart rate ≤120 times/min; * The patient needs to undergo endotracheal intubation mechanical ventilation after condition assessment; * Obtain the informed consent of the patient or his legal representative. Exclusion Criteria: * Bradycardia and second degree or more atrioventricular block; * Long-term use of beta-blockers; * Combined with emphysema, asthma and other β-blocker contraindicated diseases; * Cardiac insufficiency (NYHA grade Ⅲ or Ⅳ); * Pregnancy
Where this trial is running
Jinan, Shandong
- Department of Intensive Care Medicine — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Quanzhen Wang, doctor
- Email: wangquanzhen1986@163.com
- Phone: 15562570205
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.